Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Naval Group signs contract for four defence and intervention frigates (FDI) for the Royal Swedish Navy

 Vinge has advised Naval Group in connection with the negotiations with the Swedish Defence Materiel Administration (FMV) for the procurement of four defence and intervention frigates (FDI) for the Swedish Navy. The contract was signed on 31 August 2026 in Stockholm. Naval Group has been selected as a strategic partner by the Swedish Government to rapidly strengthen and modernise its fleet's capabilities.
September 08, 2026

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

 Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Revivo Group on the acquisition of Premator

 Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026